Summary.-Glial fibrillary acidic protein (GFA) was assayed in nerve-tumour extracts and located in these tumours by indirect immunofluorescence study. We conclude that GFA is a specific marker of both malignant and normal astrocytes. Non-astrocytic tumours (oligodendroglioma, meningioma) do not contain GFA. Tumours with astrocytic differentiation potential (medulloblastoma) may contain GFA. Comparison of microscopic and GFA assays leads us to conclude that GFA concentration is proportional to the amount of malignant astrocytes in the tumour and inversely proportional to the necrotic area of a tumour. Normal tissue GFA and glioblastoma GFA were found to be immunologically identical.
VARIOUS unsuccessful attempts have been made to characterize brain-tumourassociated antigens, notably carcinoglial antigens or foetal antigens. The characterization of such antigens would have significant implications for diagnosis and therapy of brain tumours.
We have previously reported ) that heterologous immunization of brain tumour tissue demonstrates the absence of carcinoglial and carcinofoetal antigen, as well as the inconstant presence of brain glycoprotein (Warecka, 1967) , a normal nervous-tissue-associated antigen, and the quantitative decrease of the normal nervous-system-associated antigen NSA 2 (Delpech and Buffe, 1972; Delpech and Delpech, 1975) . The present report deals with the quantitative and qualitative analysis of another nervoussystem-associated antigen: the glial fibrillary acidic protein (GFA) (Eng et al., 1971; Bignami and Dahl, 1973) .
MATERIALS AND METHODS
Turnours. Tumour tissue was obtained at surgery. One tumour fragment was placed in formalin for classical histological study. A second tumour fragment was placed in culture medium (RPMI, Eurobio, Paris) without serum and treated in the laboratory within ] h of surgery, as follows: one fragment was removed from the culture medium and quickly frozen in liquid N2 for immunofluorescence study. Other fragments from the culture medium were removed for protein extraction. The protein-extraction fragments were homogenized in plhosphate-buffered saline (PBS: NaCl 8 g/l buffered to pH 7-2 with O-O1M phosphate) with an Ultra-Turax and spun at 32,000 g for 10 min. The supernatant was collected and dialysed against deionized water and then freeze-dried. When assayed, the lyophilized powder was reintroduced into PBS (50 mg/ml) and the insoluble portion was eliminated by centrifugation (12,000 g for 10 mnin). The protein content was determined by the method of Lowry et al. (1951) .
GFA preparation.-GFA was partially purified by ammonium sulphate precipitation (Uyeda, Eng and Bignami, 1972 ) using sheep and human brains obtained within 12 h of death.
Antisera.-The nervous-system antigen NSA 1 (Delpech et al., 1973) was verified as being identical to GFA, through the kind offices of Dr Bignami. We used as anti-GFA sera the following: anti-(human foetal astro-cyte NSA 1) serum and anti-(human glioblastoma NSA 1) serum (Maunoury et al., 1976 ). An anti-sheep-GFA serum was prepared by inoculating rabbits (1 mg/week s.c. beginningr with the third week following the first immunization) with sheep GFA combined with Freund's complete adjuvant. Before being used, the anti-human sera were absorbed on to polymerized human plasma and liver extract. The anti-sheep-GFA serum was absorbed on to polymerized sheep plasma and liver extract. These polymers were prepared in a mixture of equal volumes of plasma and liver extract (50 mg/ml) in PBS with glutaraldehyde, according to the technique of Avrameas and Ternynck (1969) . The antisera and polymers were incubated for 48 h (1 g polymer/ml antiserum) at room temperature. Following incubation, the antibodies were recovered by washing with PBS.
The gamma globulins were precipitated out with 40% saturated ammonium sulphate, reintroduced into the starting volume of PBS and dialyzed against a PBS volume 1000 x the globulin volume, changing the bath once. 0'2-ml volumes were stored at -30TC. Immunodiffusion on agarose medium (1% in PBS) of each antiserum yielded only a single line of precipitation when tested against its corresponding tissue extract. This unique line of precipitation corresponds to the GFA. Assay of GFA.-GFA was assayed by the radial immunodiffusion method (Mancini, Carbonara and Heremans, 1965) . Tumour extracts were plated on agarose gel (1% in PBS) containing 1/8 or 1/4 dilutions of antisheep-GFA. After 48h diffusion and 72h washingf in PBS, the plates were stained with Coomassie blue (Gurr, London).
The precipitation rings were measured by means of a micrometric optical device. 100 u/ml was arbitrarily attributed to a human brain extract. This standard corresponds to a value of 3 u/mg of dissolved proteins. Under these conditions the minimum measurable value was 0 3 u/mg.
As calculated on a sample containing the mean dose, the standard deviation was 12%.
Immunofluorescence study. The activity of each antiserum employed was determined on cultured human foetal astrocytes. The following sera were used as controls: (1) noniimmunized rabbit serum; (2) anti-humanliver serum or anti-sheep-liver serum; (3) anti-GFA serum absorbed with purified antigen (1 mg/ml).
GFA localization was determined by standard indirect immunofluorescence. Unfixed and alcohol-fixed tumour slices were studied. Anti-GFA sera in 1/20 and 1/50 dilutions were left in contact with each slice for 30min at laboratory temperature. The fluorescence-labelled anti-rabbit globulin (Institut Pasteur, Paris) was used at a dilution of 1/20. The reactions were considered to be specific for GFA when they occurred uniquely with the anti-GFA serum. In order to distinguish normal tissue from tumorous tissue, we studied by classical histological methods the serial microscopic sections immediately following each slice that was studied immunologically.
RESULTS
These are reported in the tables.
Astrocytomas
No immunochemical difference was found to exist between tumour GFA and normal human or sheep GFA, as evaluated by the immuinodiffusion technique. Similarly, the anti-GFA activity of our antiglioblastoma serum was consistently abolished by normal human or sheep GFA. This identical character of the antigens was further confirmed by immunohistochemical study. We have therefore concluded that there is no tumour-specific antigenic structure of GFA (Table I) . GFA activity was found in the 14 astrocytomas studied. The mean activity was 4*5 u/mg. In 4 cases the value was <2 u/mg, in 8 cases 2-7 u/mg, and in 2 cases >7 u/mg. The extreme values were 0 4 u/mg and 19-8 u/mg. No striking difference was found between the Grade III astrocytomas (5 cases, mean-4-4) and the Grade IV astrocytomas (8 cases, mean _5.3). The means are greater than those found for either human or sheep wholebrain extracts (Table II) . The highest values (Cases No. 6 and 11 in Table II) correspond to those tumours which contained little necrotic material and much cellular tissue. At the other extreme, the lowest value (Case No. 7) corresponded to a polymorphous tumour which, in addition to a characteristic Type-IV zone, contained Grade   II  III  III  III  III  III  IV  IV  IV  IV  IV  IV  IV (Fig. lb) ; in some cases this was associated with perivascular staining (Fig. 1c) ; (ii) in two cases we observed immunofluorescence labelling at the periphery of malignant astrocytic cell bodies (Fig. 2) . Specific labelling was not observed in the necrotic areas. The intensity and brilliance of the immunofluorescent filamentous staining varied in different tumours, and were seen to be proportional to each tumour's GFA content. Significant cytoplasmic staining was observed only in healthy astrocytes which sometimes contaminated the tumour samples. Contaminating normal astrocytes were distinguished from malignant astrocytes by classical histological study of the immediately successive microscopic section. The irregular aspect of tumour-cell nuclei was also identified in the immunohistological studv. Other intracranial tumours Two medulloblastomas were studied. In one medulloblastoma we were able to detect specific labelling that was confined to some malignant cells (Fig. 3) . Three oligodendrogliomas were studied, of which Therefore, taking into account the 3 factors mentioned above, our results are consistent. Also our quantitative results are in agreement with the recently published results of Dittmann et al. (1977) , which showed that the GFA concentration in astrocytomas is 1 2-6 times the GFA concentration found in normal brain tissue.
The negative findings in the study of non-astrocytic tumours are consistent with the finding that GFA is restricted to the astrocyte.
Although in the case of one medulloblastoma GFA was found to be present, its presence does not invalidate our interpretation. It is well known that in the midst of a medulloblastoma many different types of cellular differentiation may be encountered. Therefore, it appears that the very presence of GFA in a tumour is indicative of the presence of astrocytic differentiation. We feel that the study of a greater number of tumours would confirm this opinion.
